Curanex Pharmaceuticals Inc
CURX
Company Profile
Business description
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.
Contact
2 Jericho Plaza
B Wing, Suite 101
JerichoNY11753
USAT: +1 718 673-6078
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
6
Stocks News & Analysis
stocks
Why stocks sometimes fall for no obvious reason
How the private markets impact all equity investors.
stocks
Poor organic growth obscured by acquisition for ASX listed share
Sales dropped by 2% without impact of acquisition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,917.10 | 37.50 | 0.42% |
| CAC 40 | 8,115.75 | 29.75 | 0.37% |
| DAX 40 | 24,888.56 | 281.79 | 1.15% |
| Dow JONES (US) | 50,579.70 | 294.04 | 0.58% |
| FTSE 100 | 10,466.26 | 22.79 | 0.22% |
| HKSE | 25,606.03 | 219.51 | 0.86% |
| NASDAQ | 26,343.97 | 50.87 | 0.19% |
| Nikkei 225 | 65,332.98 | 1,993.91 | 3.15% |
| NZX 50 Index | 12,990.86 | 0.45 | -0.00% |
| S&P 500 | 7,473.47 | 27.75 | 0.37% |
| S&P/ASX 200 | 8,695.20 | 39.10 | 0.45% |
| SSE Composite Index | 4,112.90 | 35.62 | 0.87% |